Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Statland

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|February 8, 2020
Primary lateral sclerosis: consensus diagnostic criteriaMartin R Turner, Richard J Barohn, Philippe Corcia, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 11, 2021
N-of-1 trial of salbutamol in hyperkalaemic periodic paralysisBas C Stunnenberg, Esther C Merkus, Joost Raaphorst, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 16, 2023
The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measureAnika Varma, Jennifer Weinstein, Jamison Seabury, et al.
Brain : a Journal of Neurology|June 18, 2013
Non-dystrophic myotonia: prospective study of objective and patient reported outcomesJaya R Trivedi, Brian Bundy, Jeffrey Statland, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 3, 2015
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagementZachary Macchi, Yunxia Wang, Dan Moore, et al.
Neurology|May 10, 2020
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALSMichael Benatar, Lanyu Zhang, Lily Wang, et al.
Journal of Comparative Effectiveness Research|August 22, 2025
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trialDmitry Vlodavets, Shiwen Wu, Anna Kostera-Pruszczyk, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
Science Translational Medicine|March 25, 2016
Targeting protein homeostasis in sporadic inclusion body myositisMhoriam Ahmed, Pedro M Machado, Adrian Miller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Neurology, Neurosurgery, and Psychiatry|February 8, 2020
Primary lateral sclerosis: consensus diagnostic criteriaMartin R Turner, Richard J Barohn, Philippe Corcia, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 11, 2021
N-of-1 trial of salbutamol in hyperkalaemic periodic paralysisBas C Stunnenberg, Esther C Merkus, Joost Raaphorst, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 16, 2023
The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measureAnika Varma, Jennifer Weinstein, Jamison Seabury, et al.
Brain : a Journal of Neurology|June 18, 2013
Non-dystrophic myotonia: prospective study of objective and patient reported outcomesJaya R Trivedi, Brian Bundy, Jeffrey Statland, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 3, 2015
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagementZachary Macchi, Yunxia Wang, Dan Moore, et al.
Neurology|May 10, 2020
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALSMichael Benatar, Lanyu Zhang, Lily Wang, et al.
Journal of Comparative Effectiveness Research|August 22, 2025
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trialDmitry Vlodavets, Shiwen Wu, Anna Kostera-Pruszczyk, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
Science Translational Medicine|March 25, 2016
Targeting protein homeostasis in sporadic inclusion body myositisMhoriam Ahmed, Pedro M Machado, Adrian Miller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Pageof 4